C6orf132

Summary

C6orf132 (chromosome 6 open reading frame 132, HGNC:21288) is a protein-coding gene on chromosome 6p21.1, encoding Uncharacterized protein C6orf132 (Q5T0Z8).

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 29 total — 1 pathogenic
• MANE Select transcript: NM_001164446

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21288
Approved symbol	C6orf132
Name	chromosome 6 open reading frame 132
Location	6p21.1
Locus type	gene with protein product
Status	Approved
Aliases	bA7K24.2, LncCCLM
Ensembl gene	ENSG00000188112
Ensembl biotype	protein_coding
OMIM	620839
Entrez	647024

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 nonsense_mediated_decay

ENST00000341865, ENST00000356542, ENST00000696229

RefSeq mRNA: 1 — MANE Select: NM_001164446 NM_001164446

CCDS: CCDS47428

Canonical transcript exons

ENST00000341865 — 5 exons

Exon	Start	End
ENSE00001420490	42128672	42128778
ENSE00003966556	42101119	42103878
ENSE00003966558	42110216	42110291
ENSE00003966559	42142300	42142620
ENSE00003966560	42104463	42107583

Expression profiles

Bgee: expression breadth ubiquitous, 178 present calls, max score 98.15.

FANTOM5 (CAGE): breadth broad, TPM avg 6.0199 / max 189.0808, expressed in 650 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
73598	5.4187	537
73599	0.4993	331
73597	0.0785	36
73594	0.0140	5
73595	0.0094	2

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	98.15	gold quality
esophagus squamous epithelium	UBERON:0006920	97.34	gold quality
esophagus mucosa	UBERON:0002469	96.15	gold quality
pancreatic ductal cell	CL:0002079	95.87	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	94.21	gold quality
skin of leg	UBERON:0001511	92.73	gold quality
oral cavity	UBERON:0000167	92.43	gold quality
amniotic fluid	UBERON:0000173	92.16	gold quality
skin of abdomen	UBERON:0001416	92.05	gold quality
zone of skin	UBERON:0000014	91.16	gold quality
buccal mucosa cell	CL:0002336	91.09	gold quality
gingiva	UBERON:0001828	89.50	gold quality
upper arm skin	UBERON:0004263	88.12	silver quality
mouth mucosa	UBERON:0003729	88.06	gold quality
minor salivary gland	UBERON:0001830	87.73	gold quality
gingival epithelium	UBERON:0001949	87.66	gold quality
palpebral conjunctiva	UBERON:0001812	86.33	gold quality
vagina	UBERON:0000996	84.75	gold quality
saliva-secreting gland	UBERON:0001044	84.34	gold quality
mucosa of transverse colon	UBERON:0004991	84.19	gold quality
nasal cavity epithelium	UBERON:0005384	84.10	silver quality
duodenum	UBERON:0002114	83.89	gold quality
pharyngeal mucosa	UBERON:0000355	83.72	gold quality
body of stomach	UBERON:0001161	82.87	gold quality
nipple	UBERON:0002030	82.07	gold quality
bronchial epithelial cell	CL:0002328	81.71	gold quality
nasal cavity mucosa	UBERON:0001826	81.65	gold quality
skin of hip	UBERON:0001554	81.45	gold quality
tonsil	UBERON:0002372	81.16	gold quality
body of pancreas	UBERON:0001150	81.04	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.00
E-MTAB-10596	no	217.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

60 targeting C6orf132, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-23B-5P	99.98	66.07	587
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-23A-5P	99.94	65.39	468
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-4663	99.62	65.33	957
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-141-5P	99.57	67.86	897

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	AI661453	ENSMUSG00000034382
rattus_norvegicus	C9h6orf132	ENSRNOG00000015297

Protein

Protein identifiers

Uncharacterized protein C6orf132 — Q5T0Z8 (reviewed: Q5T0Z8)

All UniProt accessions (1): Q5T0Z8

UniProt curated annotations — full annotation on UniProt →

Isoforms (3)

UniProt ID	Names	Canonical?
Q5T0Z8-1	1	yes
Q5T0Z8-2	2
Q5T0Z8-4	3

RefSeq proteins (1): NP_001157918* (*=MANE)

Domains & families (InterPro)

UniProt features (39 total): compositionally biased region 16, modified residue 6, sequence conflict 6, region of interest 5, splice variant 4, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5T0Z8-F1	47.51	0.03

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 260, 666, 1044, 1073, 1084, 1157

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 65 (showing top): GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, MARTINEZ_RB1_TARGETS_DN, CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP, DODD_NASOPHARYNGEAL_CARCINOMA_DN, MIKKELSEN_NPC_HCP_WITH_H3K27ME3, MARTENS_TRETINOIN_RESPONSE_DN, CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_DN, CBX7_TARGET_GENES, SRSF9_TARGET_GENES, MIR130A_5P, MIR1294

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

518 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
C6orf132	INSYN2B	A6NMK8	585
C6orf132	TTC9	Q92623	566
C6orf132	LRFN2	Q9ULH4	506
C6orf132	C12orf75	Q8TAD7	469
C6orf132	ANXA9	O76027	419
C6orf132	SCEL	O95171	418
C6orf132	EPC2	Q52LR7	409
C6orf132	GOLIM4	O00461	393
C6orf132	MYO5C	Q9NQX4	377
C6orf132	MATN2	O00339	366
C6orf132	SERPINB13	Q9UIV8	365
C6orf132	FUCA1	P04066	364
C6orf132	ADAMTS6	Q9UKP5	338
C6orf132	TMPRSS4	Q9NRS4	327
C6orf132	TNFAIP2	Q03169	297

IntAct

14 interactions, top by confidence:

A	B	Type	Score
KEAP1	C6orf132	psi-mi:“MI:0407”(direct interaction)	0.440
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
BAIAP2	ESPN	psi-mi:“MI:0914”(association)	0.350
EZR	EEF2K	psi-mi:“MI:2364”(proximity)	0.270
CDH1	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
SFN	BLTP3B	psi-mi:“MI:2364”(proximity)	0.270
YWHAB	E2F8	psi-mi:“MI:2364”(proximity)	0.270
YWHAE	E2F8	psi-mi:“MI:2364”(proximity)	0.270
YWHAH	E2F8	psi-mi:“MI:2364”(proximity)	0.270
YWHAQ	E2F8	psi-mi:“MI:2364”(proximity)	0.270
YWHAZ	E2F8	psi-mi:“MI:2364”(proximity)	0.270
YWHAG	E2F8	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (28): C6orf132 (Proximity Label-MS), C6orf132 (Affinity Capture-MS), C6orf132 (Proximity Label-MS), C6orf132 (Affinity Capture-MS), C6orf132 (Affinity Capture-MS), C6orf132 (Proximity Label-MS), C6orf132 (Proximity Label-MS), C6orf132 (Proximity Label-MS), C6orf132 (Proximity Label-MS), C6orf132 (Proximity Label-MS), C6orf132 (Proximity Label-MS), C6orf132 (Proximity Label-MS), C6orf132 (Affinity Capture-MS), C6orf132 (Proximity Label-MS), C6orf132 (Proximity Label-MS)

ESM2 similar proteins: A2A7S8, A5D7K1, A5PK23, B1AXH1, F1QGH6, O94885, O95402, Q08495, Q08DM1, Q3T044, Q499V8, Q5HYW2, Q5PQP4, Q5R4B6, Q5R8Q8, Q5SYE7, Q5T0Z8, Q5U2R6, Q6PDH0, Q6PFX7, Q6PGN9, Q6ZVC0, Q7TT28, Q80U35, Q80VC9, Q80Z38, Q86UU1, Q86WR7, Q8BI29, Q8C5R2, Q8CAF4, Q8JZX9, Q8K4J6, Q8N1G1, Q8TF72, Q91Z58, Q969V6, Q96A73, Q9BW04, Q9D0P7

Diamond homologs: Q5T0Z8, Q91Z58

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 17 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	7	313.5×	3e-15
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	276.6×	4e-15
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	276.6×	4e-15
Activation of BH3-only proteins	7	204.4×	4e-14
RHO GTPases activate PKNs	7	130.6×	1e-12
Intrinsic Pathway for Apoptosis	7	120.6×	2e-12
FOXO-mediated transcription	5	98.8×	9e-09
Apoptosis	8	79.0×	9e-13

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	5	107.8×	9e-08
intracellular protein localization	7	43.1×	3e-08

Disease & clinical

Clinical variants and AI predictions

ClinVar

29 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	21
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
58427	GRCh38/hg38 6p21.2-21.1(chr6:37777369-45653843)x1	Pathogenic

SpliceAI

642 predictions. Top by Δscore:

Variant	Effect	Δscore
6:42110211:CTTA:C	donor_loss	1.0000
6:42110212:TTACC:T	donor_loss	1.0000
6:42110213:TACC:T	donor_loss	1.0000
6:42110214:A:AC	donor_gain	1.0000
6:42110214:AC:A	donor_gain	1.0000
6:42110214:ACCT:A	donor_loss	1.0000
6:42110215:C:A	donor_loss	1.0000
6:42110215:C:CA	donor_gain	1.0000
6:42110215:CC:C	donor_gain	1.0000
6:42110215:CCT:C	donor_gain	1.0000
6:42110215:CCTGT:C	donor_gain	1.0000
6:42110288:CATT:C	acceptor_gain	1.0000
6:42110290:TT:T	acceptor_gain	1.0000
6:42110292:C:CC	acceptor_gain	1.0000
6:42110292:C:T	acceptor_loss	1.0000
6:42110303:C:CT	acceptor_gain	1.0000
6:42110304:A:T	acceptor_gain	1.0000
6:42128668:TCACC:T	donor_loss	1.0000
6:42128670:A:AC	donor_gain	1.0000
6:42128670:A:C	donor_loss	1.0000
6:42128671:C:CC	donor_gain	1.0000
6:42128671:CCAG:C	donor_gain	1.0000
6:42128775:CCAT:C	acceptor_gain	1.0000
6:42128776:CAT:C	acceptor_gain	1.0000
6:42128776:CATC:C	acceptor_gain	1.0000
6:42128776:CATCT:C	acceptor_loss	1.0000
6:42128778:TCT:T	acceptor_loss	1.0000
6:42128779:C:A	acceptor_loss	1.0000
6:42128779:C:CC	acceptor_gain	1.0000
6:42128780:T:G	acceptor_loss	1.0000

AlphaMissense

7528 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:42142345:A:G	W34R	0.997
6:42142345:A:T	W34R	0.997
6:42104936:G:C	F992L	0.996
6:42104936:G:T	F992L	0.996
6:42104938:A:G	F992L	0.996
6:42103833:G:C	F1165L	0.995
6:42103833:G:T	F1165L	0.995
6:42103835:A:G	F1165L	0.995
6:42103834:A:G	F1165S	0.994
6:42128681:G:C	F81L	0.993
6:42128681:G:T	F81L	0.993
6:42128683:A:G	F81L	0.993
6:42104937:A:G	F992S	0.991
6:42142343:C:A	W34C	0.991
6:42142343:C:G	W34C	0.991
6:42104723:C:A	K1063N	0.988
6:42104723:C:G	K1063N	0.988
6:42105387:A:G	L842P	0.987
6:42105435:T:C	H826R	0.987
6:42128724:G:T	A67D	0.986
6:42104937:A:C	F992C	0.985
6:42105434:G:C	H826Q	0.985
6:42105434:G:T	H826Q	0.985
6:42128718:A:G	L69P	0.985
6:42105378:G:T	A845D	0.984
6:42128714:T:A	K70N	0.984
6:42128714:T:G	K70N	0.984
6:42142400:G:C	F15L	0.984
6:42142400:G:T	F15L	0.984
6:42142402:A:G	F15L	0.984

dbSNP variants (sampled 300 via entrez): RS1000091995 (6:42129205 A>G), RS1000168309 (6:42131768 T>C), RS1000176416 (6:42101556 A>T), RS1000188940 (6:42121238 G>A), RS1000268462 (6:42104892 C>T), RS1000322711 (6:42104675 G>A), RS1000365393 (6:42114741 A>T), RS1000700552 (6:42116219 T>C), RS1000832825 (6:42121518 C>T), RS1000921559 (6:42116480 C>T), RS1000928556 (6:42122826 C>T), RS1000972597 (6:42125116 A>C), RS1001130269 (6:42130251 G>C), RS1001204959 (6:42122504 T>A,C), RS1001272232 (6:42133648 A>G)

Disease associations

OMIM: gene MIM:620839 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002337_10	Amyotrophic lateral sclerosis (sporadic)	6.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects cotreatment, decreases expression, increases expression	3
entinostat	increases expression, affects cotreatment	2
Arsenic	increases expression, affects methylation, affects cotreatment, increases abundance	2
Silicon Dioxide	decreases expression	2
Tobacco Smoke Pollution	affects expression, decreases expression	2
Valproic Acid	increases expression, affects expression, affects cotreatment	2
aristolochic acid I	increases expression	1
bisphenol F	affects cotreatment, increases methylation	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	increases expression	1
sulforaphane	decreases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
butyraldehyde	decreases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	decreases methylation	1
nickel sulfate	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Allergens	increases expression	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Carbamazepine	affects expression	1
Copper	affects cotreatment, decreases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Endosulfan	decreases expression	1
Furaldehyde	affects localization, decreases expression, affects cotreatment	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety